

243

13. A composition comprising the modified relaxin polypeptide of claim 7 and a pharmaceutically acceptable carrier.

14. A modified relaxin polypeptide comprising a non-naturally encoded amino acid, wherein: (a) the relaxin polypeptide comprises a relaxin A chain polypeptide and a relaxin B chain polypeptide, wherein said relaxin A chain polypeptide comprises the amino acid sequence of SEQ ID NO: 4 substituted with said non-naturally encoded amino acid at residue 1, and said relaxin B chain polypeptide comprises the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6; and (b) said non-naturally encoded amino acid is linked to a linker or polymer by a triazole or an oxime linkage.

15. The modified relaxin polypeptide of claim 14, wherein said non-naturally encoded amino acid is linked to said linker or polymer by an oxime linkage resulting from a reaction of a first functional group and a second functional group, wherein said first functional group comprises a carbonyl group and said second functional group comprises an aminooxy group.

16. The modified relaxin polypeptide of claim 15, wherein said non-naturally encoded amino acid comprises said first functional group and said second functional group is linked to said linker or polymer, and the oxime linkage resulting

244

from the reaction of said first functional group and said second functional group links said non-naturally encoded amino acid to said linker or polymer.

17. The modified relaxin polypeptide of claim 14, wherein the non-naturally encoded amino acid is selected from a para-substituted, ortho-substituted, or meta-substituted phenylalanine comprising a carbonyl group, an aminooxy group, a hydrazide group, a hydrazine group, a semicarbazide group, an azide group, or an alkyne group, or wherein said non-naturally encoded amino acid comprises para-acetyl-L-phenylalanine.

18. The modified relaxin polypeptide of claim 14, wherein the modified relaxin polypeptide exhibits an increased in vivo half-life by at least 2-fold relative to the human relaxin polypeptide of SEQ ID NO: 4 and SEQ ID NO: 5.

19. The modified relaxin polypeptide of claim 14, wherein said linker is linked to a polymer, a water-soluble polymer, a polymer comprising poly(ethylene glycol), a label, a dye, a fatty acid, a carbohydrate, a saccharide, a cyclodextrin, a fluorophore, or biotin.

20. A composition comprising the modified relaxin polypeptide of claim 14 and a pharmaceutically acceptable carrier.

* * * * *